89 related articles for article (PubMed ID: 30045021)
1. The Natural Compound Myricetin Effectively Represses the Malignant Progression of Prostate Cancer by Inhibiting PIM1 and Disrupting the PIM1/CXCR4 Interaction.
Ye C; Zhang C; Huang H; Yang B; Xiao G; Kong D; Tian Q; Song Q; Song Y; Tan H; Wang Y; Zhou T; Zi X; Sun Y
Cell Physiol Biochem; 2018; 48(3):1230-1244. PubMed ID: 30045021
[TBL] [Abstract][Full Text] [Related]
2. Flavonoid ampelopsin inhibits the growth and metastasis of prostate cancer in vitro and in mice.
Ni F; Gong Y; Li L; Abdolmaleky HM; Zhou JR
PLoS One; 2012; 7(6):e38802. PubMed ID: 22693649
[TBL] [Abstract][Full Text] [Related]
3. Conditional transgenic expression of PIM1 kinase in prostate induces inflammation-dependent neoplasia.
Narlik-Grassow M; Blanco-Aparicio C; Cecilia Y; Perez M; Muñoz-Galvan S; Cañamero M; Renner O; Carnero A
PLoS One; 2013; 8(4):e60277. PubMed ID: 23565217
[TBL] [Abstract][Full Text] [Related]
4. PIM1 targeted degradation prevents the emergence of chemoresistance in prostate cancer.
Torres-Ayuso P; Katerji M; Mehlich D; Lookingbill SA; Sabbasani VR; Liou H; Casillas AL; Chauhan SS; Serwa R; Rubin MR; Marusiak AA; Swenson RE; Warfel NA; Brognard J
Cell Chem Biol; 2024 Feb; 31(2):326-337.e11. PubMed ID: 38016478
[TBL] [Abstract][Full Text] [Related]
5. Identification of PIM1 substrates reveals a role for NDRG1 phosphorylation in prostate cancer cellular migration and invasion.
Ledet RJ; Ruff SE; Wang Y; Nayak S; Schneider JA; Ueberheide B; Logan SK; Garabedian MJ
Commun Biol; 2021 Jan; 4(1):36. PubMed ID: 33398037
[TBL] [Abstract][Full Text] [Related]
6. Clinical and biological significance of PIM1 kinase in osteosarcoma.
Liao Y; Feng Y; Shen J; Gao Y; Cote G; Choy E; Harmon D; Mankin H; Hornicek F; Duan Z
J Orthop Res; 2016 Jul; 34(7):1185-94. PubMed ID: 26687194
[TBL] [Abstract][Full Text] [Related]
7. Myricetin, a natural inhibitor of CD147, increases sensitivity of cisplatin in ovarian cancer.
Chen L; Fan T; Wang M; Zhu CY; Feng WY; Li Y; Yang H
Expert Opin Ther Targets; 2024; 28(1-2):83-95. PubMed ID: 38235574
[TBL] [Abstract][Full Text] [Related]
8. PIM1 drives lipid droplet accumulation to promote proliferation and survival in prostate cancer.
Chauhan SS; Casillas AL; Vizzerra AD; Liou H; Clements AN; Flores CE; Prevost CT; Kashatus DF; Snider AJ; Snider JM; Warfel NA
Oncogene; 2024 Feb; 43(6):406-419. PubMed ID: 38097734
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in flavonoid compounds for the treatment of prostate cancer.
Fang W; Du J; Nie M; Wang X
Mol Biol Rep; 2024 May; 51(1):653. PubMed ID: 38734766
[TBL] [Abstract][Full Text] [Related]
10. LPA
Lin YC; Chen CC; Chen WM; Lu KY; Shen TL; Jou YC; Shen CH; Ohbayashi N; Kanaho Y; Huang YL; Lee H
Biochim Biophys Acta Mol Cell Biol Lipids; 2018 Oct; 1863(10):1305-1315. PubMed ID: 30053596
[TBL] [Abstract][Full Text] [Related]
11. Imparting aromaticity to 2-pyridone derivatives by
Abdelaziz ME; El-Miligy MMM; Fahmy SM; Abu-Serie MM; Hazzaa AA; Mahran MA
J Enzyme Inhib Med Chem; 2024 Dec; 39(1):2304044. PubMed ID: 38230430
[TBL] [Abstract][Full Text] [Related]
12. Bioactive nutraceuticals as G4 stabilizers: potential cancer prevention and therapy-a critical review.
Choudhury SD; Kumar P; Choudhury D
Naunyn Schmiedebergs Arch Pharmacol; 2024 Jun; 397(6):3585-3616. PubMed ID: 38019298
[TBL] [Abstract][Full Text] [Related]
13. Flavonoid Myricetin as Potent Anticancer Agent: A Possibility towards Development of Potential Anticancer Nutraceuticals.
Trivedi A; Hasan A; Ahmad R; Siddiqui S; Srivastava A; Misra A; Mir SS
Chin J Integr Med; 2024 Jan; 30(1):75-84. PubMed ID: 37340205
[TBL] [Abstract][Full Text] [Related]
14. Myricetin: A Significant Emphasis on Its Anticancer Potential via the Modulation of Inflammation and Signal Transduction Pathways.
Rahmani AH; Almatroudi A; Allemailem KS; Alwanian WM; Alharbi BF; Alrumaihi F; Khan AA; Almatroodi SA
Int J Mol Sci; 2023 Jun; 24(11):. PubMed ID: 37298616
[TBL] [Abstract][Full Text] [Related]
15. CXC chemokine receptor 4 (CXCR4) blockade in cancer treatment.
Bao S; Darvishi M; H Amin A; Al-Haideri MT; Patra I; Kashikova K; Ahmad I; Alsaikhan F; Al-Qaim ZH; Al-Gazally ME; Kiasari BA; Tavakoli-Far B; Sidikov AA; Mustafa YF; Akhavan-Sigari R
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7945-7968. PubMed ID: 36905421
[TBL] [Abstract][Full Text] [Related]
16. Recent advance of herbal medicines in cancer- a molecular approach.
Ali M; Wani SUD; Salahuddin M; S N M; K M; Dey T; Zargar MI; Singh J
Heliyon; 2023 Feb; 9(2):e13684. PubMed ID: 36865478
[TBL] [Abstract][Full Text] [Related]
17. Discovery of new pyridine-quinoline hybrids as competitive and non-competitive PIM-1 kinase inhibitors with apoptosis induction and caspase 3/7 activation capabilities.
El-Miligy MMM; Abdelaziz ME; Fahmy SM; Ibrahim TM; Abu-Serie MM; Mahran MA; Hazzaa AA
J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2152810. PubMed ID: 36629075
[TBL] [Abstract][Full Text] [Related]
18. Why Do Dietary Flavonoids Have a Promising Effect as Enhancers of Anthracyclines? Hydroxyl Substituents, Bioavailability and Biological Activity.
Golonko A; Olichwier AJ; Swislocka R; Szczerbinski L; Lewandowski W
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613834
[TBL] [Abstract][Full Text] [Related]
19. Effects of the Mediterranean diet polyphenols on cancer development.
Dayi T; Oniz A
J Prev Med Hyg; 2022 Jun; 63(2 Suppl 3):E74-E80. PubMed ID: 36479482
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
